To identify novel targeted combination therapies in NB, we performed a high‐throughput combinatorial drug screen in the chemo‐resistant cell line SK‐N‐BE(2)‐C, derived from a NB patient tumour after chemotherapy, with MYCN gene amplification and mutant TP53, markers of highly aggressive and drug‐resistant disease. This evidence concerns the gene MYCN and neuroblastoma.